Abstract
We attempted to investigate immunohistochemical expression of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor (PD-ECGF), c-erbB-2, matrix metalloproteinase-2 (MMP-2), and MMP-9 using surgical specimens of 119 non-small-cell lung carcinoma (NSCLC) cases and to evaluate the relationship between the expression levels of each molecule and clinicopathological factors or prognosis. VEGF expression levels were significantly associated with the local invasion (P = 0.0001), lymph node involvement (pN-factor) (P = 0.0019), pathological stage (p-stage) (P = 0.0027) and lymphatic permeation (P = 0.0389). PD-ECGF expression levels were associated with pN-factor (P = 0.0347). MMP-2 expression levels were associated with pN-factor (P = 0.004) and lymphatic permeation (P = 0.0056). Also, MMP-9 expression levels showed a significant correlation to local invasion (P = 0.0012), pN-factor (P = 0.0093) and p-stage (P = 0.0142). Multivariate analysis showed VEGF to be the most related to local invasion (P = 0.0084), and MMP-2 was the only factor with significant independent impact on lymphatic permeation (P = 0.0228). Furthermore, log-rank analysis showed significant association with poor survival by VEGF, bFGF, MMP-2 and MMP-9. Especially, combined overexpression of VEGF and MMP-2 revealed poor prognosis, our study might provide a basis for the better evaluation of biological characteristics and a new therapeutic strategy based on chemotherapy. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aznavoorian S, Murphy AN, Stetler-Stevenson WG and Liotta LA (1993) Molecular aspects of tumor cell invasion and metastasis. Cancer 71: 1368–1383
Brown PD, Bloxidge RE, Stuart NS, Gatter KC and Carmichael J (1993) Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 85: 574–578
Belotti D, Paganoni P and Giavazzi R (1999) MMP inhibitors: experimental and clinical studies. Int J Biol Markers 14: 232–238
Bergers G, Brekken R, McMahon G, Vu TH, Ito T, Tamaki K, Tanzawa K, Thorpe P, Itohata S, Werb Z and Hanahan D (2000) Matrix metalloproteinase– 9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2: 737–744
Cox G, Jones JL and O’Byrne KJ (2000) Matrix metalloproteinase-9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 6: 2349–2355
Curran S and Murray GI (1999) Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 189: 300–308
Duensing S, Grosse J and Atzpodien J (1995) Increased serum levels of basic fibroblast growth factor (bFGF) are associated with progressive lung metastases in advanced renal cell carcinoma patients. Anticancer Res 15: 2331–2333
el-Torky M, el-Zeky F and Hall JC (1990) Significant changes in the distribution of histologic types of lung cancer. A review of 4928 cases. Cancer 65: 2361–2367
Folkman J (1985) Tumor angiogenesis. Adv Cancer Res 43: 175–203
Fontanini G, Vignati S, Boldrini L, Chine S, Silvestri V, Lucchi M, Mussi A, Angeletti CA and Bevilacqua G (1997) Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 6: 861–865
Fujise N, Nanashim A, Taniguchi Y, Matsuo S, Hatano K, Matsumoto Y, Tagawa Y and Ayabe H (2000) Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinomas by immunohistochemical study. Lung Cancer 27: 19–26
Garzetti GG, Ciavattini A, Lucarini G, Pugnaloni A, De Nictolis M, Amati S, Romanini C and Biagini G (1999) Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors. Cancer 85: 2219–2225
Gasparini G (1996) Angiogenesis research up to 1996. A commentary on the state of art and suggestions for further studies. Eur J Cancer 32A: 2379–2385
Giani C, Casalini P, Pupa SM, De Vecchi R, Ardini E, Colnaghi MI, Giordano A and Menard S (1998) Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation. Oncogene 17: 425–432
Giatromanolaki A, Gorgoulis V, Chetty R, Koukourakis MI, Whitehouse R, Kittas C, Veslemes M, Gatter KC and Iordanoglou I (1996) C-erbB-2 oncoprotein expression in operable non-small cell lung cancer. Anticancer Research 16: 987–993
Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O’Byrne K, Scott PA, Pezzella F, Georgoulias V, Harris AL and Gatter KC (1998) Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 4: 3017–3024
Ginsberg RJ and Rubinstein LV (1995) Randomized trial of lobectomy versus limited resection for T1 No non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60: 615–22; discussion 622–623
Gonzalez-Avila G, Iturria C, Vadillo F, Teran L, Selman M and Perez-Tamayo R (1998) 72-kD (MMP-2) and 92-kD (MMP-9) type IV collagenase production and activity in different histologic types of lung cancer cells. Pathobiology 66: 5–16
Guddo F, Fontanini G, Reina C, Vignola AM, Angeletti A and Bonsignore G (1999) The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression. Hum Pathol 30: 788–794
Haas TL, Davis SJ and Madri JA (1998) Three-dimensional type-I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells. J Biol Chem 273: 3604–3610
Hengstler JG, Lange J, Kett A, Dornhofer N, Meinert R, Arand M, Knapstein PG, Becker R, Oesch F and Tanner B (1999) Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. Cancer Res 59: 3206–3214
Hiraoka N, Allen E, Apel IJ, Gyetko MR and Weiss SJ (1998) Matrix Metalloproteinase regulate neovascularization by acting as pericellular fibrinolysins. Cell 95: 365–377
Hsu SM, Raine L and Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577–580
Ito T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H and Itohara S (1998) Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 58: 1048–1051
Johnson LJ, Dyer R and Hupe DJ (1998) Matrix metalloproteinases. Curr Opin Chem Biol 2: 466–471
Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MI, Torney L and Robinson RA (1990) p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50: 5184–5187
Kleiner DE and Steler-stevenson WG (1999) Matrix metalloproteinases and metastasis. Cancer Chemther Pharmacol 43, (Suppl):S42–S51
Kodate M, Kasai T, Hashimoto H, Yasumoto K, Iwata Y and Manabe H (1997) Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol Int 47: 461–469
Kono T, Nishida M, Inagaki N, Tanaka Y, Yoneda M and Kasai S (2001) Development and characterization of 1C6-203, a new monoclonal antibody specific to human thymidine phosphorylase. J Histochem Cytochem 49: 131–138
Koukourakis MI, Giatromanolaki A, O’Byrne KJ, Comley M, Whitehouse RM, Talbot DC, Gatter KC and Harris AL (1997) Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer 75: 477–481
Maeda K, Chung YS, Ogawa Y, Takatsuka S, Sawada T, Onoda N, Nitta A, Arimoto Y and Sowa M (1995) Malignancy of gastric cancer analyzed by the expression of thymidine phosphorylase. Gan To Kagaku Ryoho 22: 679–682, (Japanese)
Moghaddam A and Bicknell R (1992) Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry 31: 12141–12146
Mountain CF (1997) Revisions in the International System for Staging Lung Cancer. Chest 111: 1710–1717
Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM (2000) Matrix metalloproteinses: biological activity and clinical implications. J Clin Oncol 18: 1135–1149
O’Byrne KJ, Koukourakis MI, Giatromanolaki A, Cox G, Turley H, Steward WP, Gatter K and Harris AL (2000) Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 82: 1427–1432
Ohta M, Konno H, Tanaka T, Baba M, Kamiya K, Oba Kouji, Kaneko T, Syouji T, Igarashi A and Nakamura S (2001) Effect of combination therapy with matrix metalloproteinase inhibitor MMI-166 and Mitomycin C on the growth and liver metastasis of human colon cancer. (Japan). J Cancer Res 92: 688–695
Ohta T, Yamamoto M, Numata M, Iseki S, Tsukioka Y, Miyashita T, Kayahara M, Nagakawa T, Miyazaki I, Nishikawa K and Yoshitake Y (1995) Expression of basic fibroblast growth factor and its receptor in human pancreatic carcinomas. Br J Cancer 72: 824–831
Ohta Y, Watanabe Y, Murakami S, Oda M, Hayashi Y and Nonomura A (1997) Vascular endothelial growth factor and lymph node metastasis in primary lung cancer. Br J Cancer 76: 1041–1045
Ohta Y, Tomita Y, Oda M, Watanabe S, Murakami S and Watanabe Y (1999) Tumour angiogenesis and recurrence in stage I non-small cell lung cancer. Ann Thorac Surg 68: 1034–1038
Oshika Y, Nakamura M, Tokunaga T, Ozeki Y, Fukushima Y, Hatanaka H, Abe Y, Yamazaki H, Kijima H, Tamaoki N and Ueyama Y (1998) Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer. Int J Oncol 12: 541–544
Passlick B, Sienel W, Seen-Hibler R, Wockel W, Thetter O, Mutschler W and Pantel K (2000) Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 6: 3944–3948
Pfeiffer P, Clausen PP, Andersen K and Rose C (1996) Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 74: 86–91
Sato Y, Mukai K, Watanabe S, Goto M and Shimosato Y (1986) The AMeX method. A simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining. Am J Pathol 125: 431–435
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182
Stetler-Stevenson WG, Hewitt R and Corcoran M (1996) Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 7: 147–154
Suzuki M, Iizawa T, Fujisawa T, Baba M, Yamaguchi Y, Kimura H and Suzuki H (1998) Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small cell lung cancer. Invasion metastasis 18: 134–141
Takanami I, Tanaka F, Hashizume T, Kikuchi K, Yamamoto Y, Yamamoto T and Kodaira S (1996) The basic fibroblast growth factor and its receptor in pulmonary adenocarcinomas: an investigation of their expression as prognostic markers. Eur J Cancer 32A: 1504–1509
Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, Yamada Y, Murata F and Aikou T (1996) Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88: 1110–1117
Tateishi M, Ishida T, Mitsudomi T, Kaneko S and Sugimachi K (1991) Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 27: 1372–1375
Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Yamamoto H, Miyajima N, Toyoshima K, Yamamoto T and Yokota J et al (1989) Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene- coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res 49: 3104–3108
Ueki T, Koji T, Tamiya S, Nakane PK and Tsuneyoshi M (1995) Expression of basic fibroblast growth factor and fibroblast growth factor receptor in advanced gastric carcinoma. J Pathol 177: 353–361
Volm M, Koomagi R, Mattern J and Stammler G (1997) Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro. Anticancer Res 17: 99–103
Volm M, Koomagi R and Mattern J (1999) PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis. Anticancer Res 19: 651–655
Wilson CL and Matrisian LM (1996) Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol 28: 123–136
Yano T, Tanikawa S, Fujie T, Masutani M and Horie T (2000) Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur J Cancer 36: 601–609
Zucker S, Cao J and Chen W (2000) Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogen 19: 6642–6650
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Shou, Y., Hirano, T., Gong, Y. et al. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br J Cancer 85, 1706–1712 (2001). https://doi.org/10.1054/bjoc.2001.2137
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2137
Keywords
This article is cited by
-
Effects of ultrasound-guided paravertebral block on MMP-9 and postoperative pain in patients undergoing VATS lobectomy: a randomized, controlled clinical trial
BMC Anesthesiology (2020)
-
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
British Journal of Cancer (2018)
-
BRCA1-associated protein 1 deficiency in lung adenocarcinoma predicts poor outcome and increased tumor invasion
BMC Cancer (2016)
-
Matrix metalloproteinase 2 polymorphisms and expression in lung cancer: a meta-analysis
Tumor Biology (2012)
-
Direct anti-metastatic efficacy by the DNA enzyme Dz13 and downregulated MMP-2, MMP-9 and MT1-MMP in tumours
Cancer Cell International (2010)